Health News Releases

  • Today February 18
December 21, 2015 11:50
Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore (http://goo.gl/7U6Olz), 18-21 December 2015. New dat
December 18, 2015 18:20
Retired U.S. Senator Tom Harkin Joins Masimo’s Board of Directors
Masimo (www.masimo.com) (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, announced today that retired Senator Tom Harkin, former five-term U.S. Senator and former Cha
December 17, 2015 13:45
First Patients Enrolled in the Gore RELINE MAX Clinical Study
W. L. Gore & Associates (Gore) (www.goremedical.com) announces that the first patients are now enrolled in the Gore RELINE MAX Clinical Study, a post-approval study to continue to evaluate the GORE® V
December 17, 2015 13:30
Takeda Announces Sale of Respiratory Portfolio to AstraZeneca
Takeda Pharmaceutical Company Limited (TOKYO:4502, http://goo.gl/eX9kbP) today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Taked
December 16, 2015 13:00
President Clinton To Deliver Keynote Remarks at the 4th Annual World Patient Safety, Science & Technology Summit
The Patient Safety Movement Foundation (http://patientsafetymovement.org) announced today that President Bill Clinton, Founder of the Clinton Foundation & 42nd President of the United States, will del
December 15, 2015 21:00
Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Sanofi (http://en.sanofi.com)and Boehringer Ingelheim (www.boehringer-ingelheim.com) today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transa
December 15, 2015 20:00
WIN 2016 Symposium June 27-28, Paris: “Innovative Approaches to Improve Cancer Patient Outcomes”
WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to ad
December 15, 2015 17:40
Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the Shonan Research Center (T-CiRA)
The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint research program to develop c
December 15, 2015 17:10
Spain’s SENSAR Makes a Commitment to the Patient Safety Movement Foundation
The Patient Safety Movement Foundation (http://patientsafetymovement.org) announced today a commitment from Spain’s anesthesia national incident reporting system, Sistema Español de Notificacion en Se
December 15, 2015 14:50
Initiation of first multinational study to evaluate safety of OFEV® (nintedanib) with add-on of pirfenidone in patients with IPF
Boehringer Ingelheim today announces the initiation of trial 1199.222 (ClinicalTrials.gov Identifier: NCT02579603), a new 12 week study to assess the safety, tolerability and pharmacokinetics of add-o
December 11, 2015 13:55
Quintiles Launches Suite of Services to Integrate Asset Development Planning
Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines developm
December 10, 2015 13:55
Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/g
December 09, 2015 10:00
New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis
Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS) study. The global Phase III trial, which is now o
December 08, 2015 16:20
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases
Takeda Pharmaceutical Company Limited (TOKYO:4502, http://goo.gl/eX9kbP) and Cour Pharmaceutical Development Company, Inc. today announced a partnership to research and develop novel immune modulating
December 07, 2015 17:50
Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society
December 07, 2015 15:10
Takeda Reports Five-Year Overall Survival Data for ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) announced post-treatment follow up data from the pivotal phase 2 study of single-agent brentuximab vedotin for the treatment of r
December 07, 2015 09:30
Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® - a biosimilar version of Remicade® (infliximab), also known as SB2 - for the tre
December 03, 2015 10:15
Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The n
December 02, 2015 11:30
The Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acne
The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of 10,000 USD to contribute to the improvement of best practices in the management of acne. The AAB res
December 01, 2015 11:20
Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generic Medicines Use in Japan
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the two companies have entered into a definitive agreement to esta
December 01, 2015 10:10
Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lu
November 27, 2015 11:15
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surger
November 24, 2015 10:25
Pfizer and Allergan to Combine
Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under wh
November 23, 2015 15:10
U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) (http://goo.gl/eX9kbP) today announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO® (ixazomib) capsules, the first and only
November 23, 2015 10:15
Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® - a biosimilar ve
25 per page50 per page75 per page100 per page